ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
ORICOric(ORIC) ZACKS·2024-07-18 00:21

ORIC Pharmaceuticals, Inc. (ORIC) announced that it has collaborated with pharma giants Bayer (BAYRY) and Janssen Research & Development, LLC, a Johnson & Johnson (JNJ) company, to support its ongoing study evaluating pipeline candidate ORIC-944.ORIC will evaluate ORIC-944 in combination with Bayer’s Nubeqa (darolutamide), an androgen receptor (AR) inhibitor, and Johnson & Johnson’s AR inhibitor Erleada (apalutamide).ORIC-944 is a potent and selective allosteric inhibitor of polycomb repressive complex 2 (P ...